

PHARMACEUTICAL 2022

NEUROPATHIX INC. Rank 457 of 466





Neuropathix™



PHARMACEUTICAL 2022



NEUROPATHIX INC. Rank 457 of 466

The relative strengths and weaknesses of NEUROPATHIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEUROPATHIX INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of NEUROPATHIX INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 335% points.

The company's Economic Capital Ratio, given in the ranking table, is -470%, being 547% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	138
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,983
Liabilities, Non-Current	1,228
Other Assets	17
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-617
Other Revenues	183
Property and Equipment	69
Research and Development	452
Selling, General and Administrative Expense	2,672

Output Variable	Value in 1000 USD
Assets	225
Liabilities	4,211
Expenses	3,124
Revenues	183
Stockholders Equity	-3,987
Net Income	-3,558
Comprehensive Net Income	-3,558
Economic Capital Ratio	-470%

